PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets.
View all » Recent News Releases
View all »Events & Presentations
Jun 2, 2016 at 10:00 AM PT
Annual Meeting of Stockholders